Stock MBOT MICROBOT MEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Microbot Medical Inc.

Equities

MBOT

US59503A2042

Delayed Nasdaq
Other stock markets
 11:33:23 2024-05-13 EDT 		5-day change 1st Jan Change
0.95 USD +2.89% Intraday chart for Microbot Medical Inc. -2.06% -42.07%
04-29 Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health CI
04-16 HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
GL
Microbot Medical Shares Status Following Recent Geopolitical Events
GL
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
GL
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
GL
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
GL
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
AQ
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
GL
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
GL
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
AQ
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
GL
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
GL
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
AQ
Microbot Medical : Material Event - Form 8-K
PU
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
GL
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
GL
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
GL
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
AQ
Microbot Medical : Granted Registered Trademark from The U.S. Patent and Trademark Office - Form 8-K
PU
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
GL
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBOT Stock
  4. News Microbot Medical Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW